About Septerna
Septerna is a company based in San Bruno (United States) founded in 2020. Septerna has raised $250 million across 2 funding rounds from investors including Mirae Asset, RA Capital and Driehaus. The company has 75 employees as of December 31, 2024. Septerna offers products and services including Native Complex Platform and Oral Small Molecule Pipeline. Septerna operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Aclaris Therapeutics, Neurocrine and PTC Therapeutics, among others.
- Headquarter San Bruno, United States
- Employees 75 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Septerna, Inc.
-
Annual Revenue
$1.07 M (USD)611.92as on Dec 31, 2024
-
Net Profit
-$71.8 M (USD)-12762.79as on Dec 31, 2024
-
EBITDA
-$79.42 M (USD)-77.67as on Dec 31, 2024
-
Total Equity Funding
$250 M (USD)
in 2 rounds
-
Latest Funding Round
$150 M (USD), Series B
Jul 11, 2023
-
Investors
Mirae Asset
& 14 more
-
Employee Count
75
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Septerna
Septerna is a publicly listed company on the NASDAQ with ticker symbol SEPN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Septerna
Septerna offers a comprehensive portfolio of products and services, including Native Complex Platform and Oral Small Molecule Pipeline.
Industrial-scale platform for optimizing GPCR drug candidates.
Programs targeting endocrinology and metabolic diseases.
People of Septerna
Unlock access to complete
Funding Insights of Septerna
Septerna has successfully raised a total of $250M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $150 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Septerna
Septerna has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Mirae Asset, RA Capital and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked |
Investor details for Septerna
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Septerna
Investment portfolio details for Septerna
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Septerna
Detailed financials for Septerna
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Septerna Comparisons
Peer comparison for Septerna
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Septerna
Septerna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Aclaris Therapeutics, Neurocrine and PTC Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Septerna
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Septerna
Complete news archive for Septerna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Septerna
Septerna was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Septerna is headquartered in San Bruno, United States. It is registered at San Bruno, California, United States.
Septerna is a funded company, having raised a total of $250M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Septerna is 75.
Annual revenue of Septerna is $1.07M as on Dec 31, 2024.
Septerna was founded in 2020 and is based in San Bruno, United States. A GPCR-targeted drug discovery platform is operated, integrating biochemical, structural, and computational methods. The Native Complex platform is utilized to identify small molecules for disorders in endocrinology, central nervous system, metabolism, and inflammation. Focus is placed on advancing therapies through these combined approaches in the biotechnology sector.
Septerna's top competitors include Jazz Pharmaceuticals, Escient Pharmaceuticals and PTC Therapeutics.
Septerna offers Native Complex Platform and Oral Small Molecule Pipeline.
Yes, Septerna is publicly traded on NASDAQ under the ticker symbol SEPN.
Septerna has 15 investors. Key investors include Mirae Asset, RA Capital, Driehaus, Goldman Sachs Asset Management, and Third Rock Ventures.
The ticker symbol of Septerna is SEPN on NASDAQ.